ADHD combo drug trial stops early – only 2 teens enrolled

NCT ID NCT06673368

Terminated Symptom relief Sponsor: Neurocentria, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a combination of two drugs, NRCT-101SR and NRCT-202XR, for teens with ADHD. The goal was to see if the combo could ease symptoms and reduce side effects better than one drug alone. However, the study was terminated early and only enrolled 2 participants, so no meaningful results were obtained.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NRCT-101SR and NRCT-202XR (drug combination)
What this could lead to: If it had succeeded, this could have pointed toward a new combination treatment for ADHD that reduces side effects.
What could go wrong: The trial was terminated early with only 2 participants, so no conclusions can be drawn. It is very early-stage and uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADHD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

attention deficit hyperactivity disorder, inattentive type attention deficit-hyperactivity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADHD

Contacts and locations

Locations

Accel Research Site-Maitland Clinical Research Unit

Maitland, Florida, 32751, United States
Boston Clinical Trials LLC

Boston, Massachusetts, 02131, United States
CenExel iRS - iResearch Savannah

Savannah, Georgia, 31405, United States
Center For Psychiatry and Behavioral Medicine

Las Vegas, Nevada, 89128, United States
iResearch Atlanta

Decatur, Georgia, 30030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.